Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $1.2 billion.

  • Ascendis Pharma A's Total Current Liabilities rose 2832.51% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 2832.51%. This contributed to the annual value of $1.2 billion for FY2025, which is 2457.21% up from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Total Current Liabilities is $1.2 billion, which was up 2832.51% from $1.2 billion recorded in Q3 2025.
  • Ascendis Pharma A's Total Current Liabilities' 5-year high stood at $1.2 billion during Q4 2025, with a 5-year trough of $84.7 million in Q2 2021.
  • Over the past 5 years, Ascendis Pharma A's median Total Current Liabilities value was $222.3 million (recorded in 2023), while the average stood at $523.2 million.
  • Per our database at Business Quant, Ascendis Pharma A's Total Current Liabilities skyrocketed by 256436.92% in 2021 and then skyrocketed by 517.28% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Total Current Liabilities stood at $100.0 million in 2021, then surged by 74.73% to $174.7 million in 2022, then soared by 353.5% to $792.4 million in 2023, then rose by 22.42% to $970.1 million in 2024, then increased by 28.33% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.1 billion during Q2 2025.